CoChat
Sign Up
Cited by 298Liver Diseases and ImmunityInflammatory Bowel DiseasePediatric Hepatobiliary Diseases and Treatments

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Open access
Fickert, Peter, Hirschfield, Gideon M., Denk, Gerald, Marschall, Hanns-Ulrich, Altorjay, Istvan, Färkkilä, Martti, Schramm, Christoph, Spengler, Ulrich, Chapman, Roger, Bergquist, Annika, Schrumpf, Erik, Nevens, Frederik, Trivedi, Palak, Reiter, Florian P., Tornai, Istvan, Halilbasic, Emina, Greinwald, Roland, Pröls, Markus, Manns, Michael P., Trauner, Michael·2017·Journal of Hepatology
DOI 10.1016/j.jhep.2017.05.009
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND & AIM: homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. A randomized controlled trial, including 38 centers from 12 European countries, evaluated the safety and efficacy of three doses of oral norUDCA (500mg/d, 1,000mg/d or 1,500mg/d) compared with placebo in patients with PSC. METHODS: One hundred sixty-one PSC patients without concomitant UDCA therapy and with elevated serum alkaline phosphatase (ALP) levels were randomized for a 12-week treatment followed by a 4-week follow-up. The primary efficacy endpoint was the mean relative change in ALP levels between baseline and end of treatment visit. RESULTS: norUDCA reduced ALP levels by -12.3%, -17.3%, and -26.0% in the 500, 1,000, and 1,500mg/d groups (p=0.029, p=0.003, and p<0.0001 when compared to placebo), respectively, while a +1.2% increase was observed in the placebo group. Similar dose-dependent results were found for secondary endpoints, such as ALT, AST, γ-GT, or the rate of patients achieving ALP levels <1.5× ULN. Serious adverse events occurred in seven patients in the 500mg/d, five patients in the 1,000mg/d, two patients in the 1500mg/d group, and three in the placebo group. There was no difference in reported pruritus between treatment and placebo groups. CONCLUSIONS: norUDCA significantly reduced ALP values dose-dependently in all treatment arms. The safety profile of norUDCA was excellent and comparable to placebo. Consequently, these results justify a phase III trial of norUDCA in PSC patients. Lay summary: Effective medical therapy for primary sclerosing cholangitis (PSC) is urgently needed. In this phase II clinical study in PSC patients, a side chain-shortened derivative of ursodeoxycholic acid, norursodeoxycholic acid (norUDCA), significantly reduced serum alkaline phosphatase levels in a dose-dependent manner during a 12-week treatment. Importantly, norUDCA showed a favorable safety profile, which was similar to placebo. The use of norUDCA in PSC patients is promising and will be further evaluated in a phase III clinical study. ClinicalTrials.gov number: NCT01755507.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2017.05.009

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

Sorted by citations

Items 101–200 of 298

Related

See all

Metadata

Authors
Fickert, P., Hirschfield, G. M., Denk, G., Marschall, H.-U., Altorjay, I., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., Schrumpf, E., Nevens, F., Trivedi, P., Reiter, F. P., Tornai, I., Halilbasic, E., Greinwald, R., Pröls, M., Manns, M. P., & Trauner, M.
Affiliations
  • Medical University of Graz (AT)
  • University of Birmingham (GB)
  • LMU Klinikum (DE)
  • University of Gothenburg (SE)
  • University of Helsinki (FI)
  • University Medical Center Hamburg-Eppendorf (DE)
  • University of Bonn (DE)
  • John Radcliffe Hospital (GB)
  • Karolinska University Hospital (SE)
  • Oslo University Hospital (NO)
  • KU Leuven (BE)
  • Medical University of Vienna (AT)
  • Dr Falk Pharma (Germany) (DE)
  • Medizinische Hochschule Hannover (DE)
Corresponding author
Trauner, Michael
ORCID
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2017-09
Volume
67
Issue
3
Pages
549-558
ISSN
0168-8278 (ISSN-L)
DOI
10.1016/j.jhep.2017.05.009
OpenAlex
W2616282068
Cited by
297
References
45
Citations by year
2026: 30 · 2025: 22 · 2024: 38 · 2023: 25 · 2022: 35 · 2021: 43 · 2020: 36 · 2019: 29 · 2018: 28 · 2017: 9
FWCI
17.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hepatology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion, cc-by-nc-nd)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, cc-by-nc-nd)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
Funders
  • Falk Foundation
  • Pfizer
  • Gilead Sciences
  • National Institute for Health and Care Research
  • Astellas Pharma
  • Dr. Falk Pharma
  • Cilag
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
primary sclerosing cholangitis, cholestasis, alkaline phosphatase, dose-dependent effects, safety profile, pruritus, liver fibrosis
MeSH terms
Adult, Alkaline Phosphatase, Cholestasis, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Ursodeoxycholic Acid, Cholangitis, Sclerosing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review